ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
10. März 2022 07:00 ET
|
ObsEva SA
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back...
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
10. März 2022 01:00 ET
|
ObsEva SA
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the...
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
10. Februar 2022 16:11 ET
|
ObsEva SA
- Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets...
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
04. Februar 2022 16:15 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 4, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
01. Februar 2022 07:00 ET
|
ObsEva SA
GENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the...
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
01. Februar 2022 01:00 ET
|
ObsEva SA
GENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the...
ObsEva Announces Corporate Updates
28. Januar 2022 16:01 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – January 28, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
06. Januar 2022 07:00 ET
|
ObsEva SA
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically...
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
06. Januar 2022 01:00 ET
|
ObsEva SA
-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically...
ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
03. Januar 2022 07:00 ET
|
ObsEva SA
GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...